Solid forms of 1-(4-(4-((3-(3,6-difluoropyridin-2-YL)-1-((1r,4r)-4-ethoxycyclohexyl)-1h-pyrazol-4-YL) carbamoyl)thiazol-2-YL)-1h-pyrazol-1-YL)ethyl phosphate and salts thereof, and their pharmaceutical compositions and uses

The development of diverse solid forms of IRAK inhibitors addresses the unpredictability in pharmaceutical compounds by offering stable and bioavailable formulations for treating autoimmune and inflammatory diseases.

WO2026122925A1PCT designated stage Publication Date: 2026-06-11RIGEL PHARMACEUTICALS INC
View PDF 4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
RIGEL PHARMACEUTICALS INC
Filing Date
2025-12-05
Publication Date
2026-06-11

Smart Images

  • Figure US2025058337_11062026_PF_FP_ABST
    Figure US2025058337_11062026_PF_FP_ABST
Patent Text Reader

Abstract

Solid forms of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)- 1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate, solid forms of salts thereof, including solid forms comprising 1-(4-(4-((3- (3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4- yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-l-yl)ethyl phosphate monosodium salt, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.
Need to check novelty before this filing date? Find Prior Art